Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06128876
Other study ID # VIE_CMR-AI
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 1, 2024
Est. completion date February 28, 2026

Study information

Verified date November 2023
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background: Artificial Intelligence (AI) in cardiac imaging has previously been shown to provide highly reproducible and accurate results, outperforming clinical experts. Cardiac magnetic resonance (CMR) imaging represents the gold standard for assessment of myocardial structure and function. However, measurements of more sensitive markers of early left (LV) and right ventricular (RV) function, such as global longitudinal shortening (GLS), mitral annular plane systolic excursion (MAPSE), and tricuspid annular plane systolic excursion (TAPSE), are frequently not performed due to the lack of automated analysis. Objectives: The investigators aim to evaluate whether AI-based measurements of ventricular structure and function convey important prognostic information in patients with severe aortic stenosis (AS) beyond LV and RV ejection fraction (EF) and represent early markers of adverse cardiac remodeling. Materials & Methods: This large-scale international, multi-center, observational study will recruit ~1500 patients with severe AS scheduled for aortic valve replacement (AVR). Patients are invited to undergo CMR imaging prior to AVR and at 12-months post-AVR. An AI-based algorithm, developed in the UK, will be used for fully automated assessment of parameters of cardiac structure (end-diastolic volume, end-systolic volume, LV mass, maximum wall thickness) and function (EF, GLS, MAPSE, TAPSE). Application of the AI-model allows to capture these parameters for large patient cohorts within seconds (as opposed to the current practice of time-consuming manual post-processing). Association of AI-based CMR parameters with clinical outcomes post-AVR will be analyzed. The composite of all-cause mortality and heart failure hospitalization will serve as the primary endpoint. Trajectories of AI-based parameters from pre- to post-AVR will be assessed as a secondary endpoint. Future Outlook: In severe AS, a novel AI-based algorithm allows immediate and precise measurements of ventricular structure and function on CMR imaging. Our goal is to identify early markers of cardiac dysfunction indicating adverse prognosis post-AVR. This has guideline-forming potential as the optimal timepoint for AVR in patients with AS is currently a matter of debate.


Description:

Artificial Intelligence (AI) and Machine Learning are reshaping our daily clinical practice, which has the potential to be more efficient, precise, and personalized. Adopting these technologies in cardiac imaging does not only affect decision making by improved accuracy and risk stratification but also significantly reduces scan times and post-imaging workup. Current guidelines acknowledge cardiac magnetic resonance (CMR) imaging as gold standard for assessment of myocardial structure and function. Although of fundamental importance in various cardiac diseases, measurements of size, mass, and ejection fraction (EF) are flawed by the inherent variability and subjectivity of human analysis. Recent developments in deep learning using convolutional neural networks (CNNs) allow for automated segmentation of the ventricular blood pool and myocardium using pre-existing CMR datasets. Importantly, these tools are integrated into CMR scanners generating real-time measurements without the need of time-consuming image post-processing. AI-based models have previously shown superior precision in ventricular contouring, volumetry, and maximum wall thickness measurements, outperforming clinical experts. In patients with aortic stenosis (AS), changes in EF more often occur late in the disease process. Longitudinal shortening represents an earlier and more sensitive marker of left ventricular (LV) dysfunction. However, these measurements remain subjective, time-consuming, and are therefore not routinely performed due to the lack of automated analysis. Recently, AI-measured global longitudinal shortening (GLS) and mitral annular plane systolic excursion (MAPSE) have been demonstrated to provide more reproducible and accurate results, when compared to human experts. The investigators hypothesize that AI-based GLS and MAPSE could convey important prognostic information beyond LVEF in severe AS and represent early markers of adverse cardiac remodeling. Furthermore, the investigators could previously demonstrate that right ventricular (RV) dysfunction on CMR, rather than conventional parameters assessed by echocardiography, was independently associated with outcome in individuals with AS undergoing transcatheter aortic valve implantation. The investigators aim to extend on our findings and investigate whether AI-based RV GLS and tricuspid annular plane systolic excursion (TAPSE) represent early markers of RV dysfunction indicating adverse prognosis. Finally, the assessment of reverse cardiac remodeling by CMR requires high precision (=reproducibility). AI has been proven to outperform humans in both precision and accuracy, and therefore has great potential for the comprehensive evaluation of longitudinal structural changes in AS following valve replacement. The investigators aim to analyze reverse cardiac remodeling in patients with AS using novel AI technology. Aims With significant previous contributions in cardiac imaging and valvular heart disease being made in the past, the investigators aim to expand the knowledge in this field by exploring the following: - Association of AI-measured LV and RV structural and functional markers on CMR in patients with severe AS with clinical outcomes following aortic valve replacement (AVR). - Reverse cardiac remodeling at baseline to 12-months after AVR as determined by AI-based CMR methods. - The ultimate goal is to provide automated, precise, and time-saving algorithms to identify patients at risk undergoing AVR. Methods This is a large-scale international, multi-center, multi-cohort, observational study. Patients with severe degenerative AS scheduled for valvular treatment discussion in an interdisciplinary Heart Team will be invited to participate. Enrollment will be performed prospectively at seven university-affiliated tertiary care centers in Continental Europe, the UK, and Asia. Baseline evaluation consists of medical history, physical examination, routine blood tests, electrocardiogram, echocardiography, and CMR imaging. Patients will be prospectively followed up by an ambulatory visit at 12 months. In addition, CMR will be repeated at 1 year.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1500
Est. completion date February 28, 2026
Est. primary completion date September 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent - Severe AS scheduled for Heart Team decision Exclusion Criteria: - Inability or unwillingness to perform any of the diagnostic tests - Inability or unwillingness to participate in follow-up visits - Metal implants, e.g. cochlear implants and pacemakers - Chronic kidney failure (GFR < 30 ml/min/1.73m2)

Study Design


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Outcome

Type Measure Description Time frame Safety issue
Other Number of patients with AI-measured parameters of impaired left and right ventricular structure and function on cardiac magnetic resonance imaging at baseline and changes at 1-year follow-up after aortic valve replacement (AVR). Longitudinal trajectories of AI-based parameters (end-diastolic volume [ml], end-systolic volume [ml], left ventricular mass [gram], maximum wall thickness [mm], ejection fraction [%], global longitudinal shortening [%], mitral/tricuspid annular plane systolic excursion [mm]) on cardiac magnetic resonance imaging from pre- to 1-year post-AVR.
Captured clinical endpoints will include all-cause death, cardiovascular mortality, and heart failure hospitalization. Data will be ascertained by follow-up visits, state-wide electronic hospital charts, and phone calls. In addition, mortality data will be obtained via National Death Registries of the participating countries. CMR will be repeated at 1 year.
1 year
Primary Number of patients with AI-measured parameters of impaired left and right ventricular structure and function on cardiac magnetic resonance imaging and association with the composite of all-cause death and heart failure hospitalization. Association of AI-based parameters (end-diastolic volume [ml], end-systolic volume [ml], left ventricular mass [gram], maximum wall thickness [mm], ejection fraction [%], global longitudinal shortening [%], mitral/tricuspid annular plane systolic excursion [mm]) on cardiac magnetic resonance imaging with the composite of all-cause death and heart failure hospitalization.
Captured clinical endpoints will include all-cause death, cardiovascular mortality, and heart failure hospitalization. Data will be ascertained by follow-up visits, state-wide electronic hospital charts, and phone calls. In addition, mortality data will be obtained via National Death Registries of the participating countries.
2 years
Secondary Number of patients with AI-measured parameters of impaired left and right ventricular structure and function on cardiac magnetic resonance imaging and association with components of the primary endpoint analyzed individually. Association of AI-based parameters (end-diastolic volume [ml], end-systolic volume [ml], left ventricular mass [gram], maximum wall thickness [mm], ejection fraction [%], global longitudinal shortening [%], mitral/tricuspid annular plane systolic excursion [mm]) on cardiac magnetic resonance imaging with components of the primary endpoint (all-cause death and heart failure hospitalization) analyzed individually.
Captured clinical endpoints will include all-cause death, cardiovascular mortality, and heart failure hospitalization. Data will be ascertained by follow-up visits, state-wide electronic hospital charts, and phone calls. In addition, mortality data will be obtained via National Death Registries of the participating countries.
2 years
Secondary Number of patients with AI-measured parameters of impaired left and right ventricular structure and function on cardiac magnetic resonance imaging and association with cardiovascular mortality. Association of AI-based parameters (end-diastolic volume [ml], end-systolic volume [ml], left ventricular mass [gram], maximum wall thickness [mm], ejection fraction [%], global longitudinal shortening [%], mitral/tricuspid annular plane systolic excursion [mm]) on cardiac magnetic resonance imaging with cardiovascular mortality.
Captured clinical endpoints will include all-cause death, cardiovascular mortality, and heart failure hospitalization. Data will be ascertained by follow-up visits, state-wide electronic hospital charts, and phone calls. In addition, mortality data will be obtained via National Death Registries of the participating countries.
2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Completed NCT03332745 - Mechanism of Decompensation Evaluation - Aortic Stenosis
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01676727 - ADVANCE Direct Aortic Study
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Terminated NCT05070130 - OpSens PRIME CLASS
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A